Abstract
Abstract not available.
Highlights
Oral broad-spectrum tetracycline-class antibiotics are prescribed for the treatment of moderate to severe inflammatory acne Poor tolerability and bacterial resistance concerns may limit the use of broad-spectrum tetracycline antibiotics for the treatment of acne
In SC1401 and SC1402 (Table 1) IGA success rates were 21.9% and 22.6% versus 10.5% and 15.3%
Sarecycline, a narrow-spectrum tetracycline class antibiotic recently FDA-approved for the treatment of moderate to severe acne in ages 9 and older, was safe, well tolerated, and statistically significant at 12 weeks in achieving IGA Success and reduction in inflammatory lesion count
Summary
Oral broad-spectrum tetracycline-class antibiotics are prescribed for the treatment of moderate to severe inflammatory acne Poor tolerability and bacterial resistance concerns may limit the use of broad-spectrum tetracycline antibiotics for the treatment of acne
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
